Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654532 · ClinicalTrials.gov registry record · Phase 1
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Accutar Biotechnology.
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT05654532: Active Phase 1 study of Breast Cancer, sponsored by Accutar Biotechnology.
NCT05654532 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Accutar Biotechnology. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05654532, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Accutar Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699
Conditions Studied
Interventions
- DRUG AC699
Study Locations (9)
Florida
- Site 07 - Orlando
- Site 02 - Sarasota
Texas
- Site 03 - Houston
- Site 09 - San Antonio
Colorado
- Site 08 - Denver
Maryland
- Site 06 - Rockville
Tennessee
- Site 01 - Nashville
Virginia
- Site 05 - Norfolk
Washington
- Site 04 - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
What the registry record for NCT05654532 still lists
NCT05654532 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AC699 is the first listed.
NCT05654532 lists 9 locations in 7 states (Florida, Texas, Colorado).
Frequently Asked Questions
What is clinical trial NCT05654532 about?
NCT05654532 is a clinical study titled "Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer". This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given sa...
What is the current status of trial NCT05654532?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2022-12-29. Estimated completion is 2026-05-31.
What conditions does trial NCT05654532 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05654532?
The interventions under investigation include: AC699 (DRUG).
Who is sponsoring clinical trial NCT05654532?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05654532 being conducted?
This trial has 9 study locations across Colorado, Florida, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05654532's enrollment target sits among peer trials
100 565th of 1224 higher than 630 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI